论文部分内容阅读
[目的]探讨VAD联合胸腺肽方案治疗多发性骨髓瘤(MM)的临床效果。[方法]应用临床实验研究方法,按入院顺序采用区组随机分组法将病例分成实验组与对照组,实验组采用VAD联合胸腺肽α1方案治疗,对照组采用单纯VAD方案治疗。治疗观察4个疗程后进行患者的近期疗效、院内感染、淋巴细胞免疫功能状态和细胞因子分泌的评价。[结果]实验组与对照组治疗的有效率分别为96.4%及70.0%,两组有统计学差异(P﹤0.05)。实验组与对照组治疗引起多发性骨髓瘤的院内感染发生率分别为17.9%及55.0%,两组比较有统计学差异(P﹤0.01)。两组患者的淋巴细胞免疫功能状态和细胞因子分泌在治疗前无统计学差异,治疗后实验组患者的淋巴细胞免疫功能状态和细胞因子分泌明显高于对照组(P﹤0.05或P﹤0.01)。[结论]VAD联合胸腺肽α1方案治疗多发性骨髓瘤可显著增强MM化疗患者的淋巴细胞免疫功能状态和细胞因子分泌,增强病人的抵抗力,从而提高治疗的有效率,明显减少患者院内感染的发生率,是一种经济实用,有推广应用价值的方案。
[Objective] To investigate the clinical effect of VAD combined with thymosin in the treatment of multiple myeloma (MM). [Methods] The clinical experimental methods were used. The patients were divided into experimental group and control group according to the sequence of hospital admission. The experimental group was treated with VAD combined with thymosin α1 and the control group with VAD alone. The treatment of 4 courses of treatment for patients with short-term efficacy, nosocomial infection, lymphocyte immune function and cytokine secretion evaluation. [Results] The effective rates of the experimental group and the control group were 96.4% and 70.0%, respectively, with statistical significance (P <0.05). The incidences of nosocomial infections in experimental and control groups were 17.9% and 55.0%, respectively, with statistical significance (P <0.01). There was no significant difference between the two groups in the status of lymphocyte immune function and the secretion of cytokines before treatment. After treatment, the immunological function and cytokine secretion of lymphocytes in experimental group were significantly higher than those in control group (P <0.05 or P <0.01) . [Conclusion] VAD combined with thymosin α1 regimen in treatment of multiple myeloma can significantly enhance the lymphocyte immune function and cytokine secretion in patients with MM chemotherapy and enhance the patient ’s resistance so as to improve the treatment efficiency and significantly reduce the occurrence of nosocomial infection Rate, is a kind of economic and practical, there is the promotion of the value of the program.